Early disability in ambulatory patients with multiple sclerosis: optical coherence tomography versus visual evoked potentials, a comparative study

[1] Browne P(2014)Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity Neurology. 83 1022-1024

[2] Chandraratna D(2016)Overview and diagnosis of multiple sclerosis Am J Manag Care 22 s141-s150

[3] Angood C(2018)Regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant Front Immunol 9 410-158

[4] Tremlett H(2016)Optical coherence tomography as a biomarker for diagnosis, progression, and prognosis of neurodegenerative diseases J Ophthalmol 2016 8503859-285

[5] Baker C(2016)Prevalence of multiple sclerosis in Al Quseir city, Red Sea Governorate, Egypt Neuropsychiatr Dis Treat 12 155-985

[6] Taylor BV(2019)Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 18 269-750

[7] Hunter SF(2018)Can optical coherence tomography be used to guide treatment decisions in adult or pediatric multiple sclerosis? Curr Treat Options Neurol 20 9-96

[8] Massey JC(2015)Longitudinal evaluation of visual function in multiple sclerosis Optom Vis Sci 92 976-1319

[9] Sutton IJ(2016)Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica Neuroimage Clin 11 743-193

[10] Ma DDF(2017)Optical coherence tomography: a quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis J Neuroimmunol 304 93-2527

[1] Browne P(2014)Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity Neurology. 83 1022-1024

[2] Chandraratna D(2016)Overview and diagnosis of multiple sclerosis Am J Manag Care 22 s141-s150

[3] Angood C(2018)Regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant Front Immunol 9 410-158

[4] Tremlett H(2016)Optical coherence tomography as a biomarker for diagnosis, progression, and prognosis of neurodegenerative diseases J Ophthalmol 2016 8503859-285

[5] Baker C(2016)Prevalence of multiple sclerosis in Al Quseir city, Red Sea Governorate, Egypt Neuropsychiatr Dis Treat 12 155-985

[6] Taylor BV(2019)Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 18 269-750

[7] Hunter SF(2018)Can optical coherence tomography be used to guide treatment decisions in adult or pediatric multiple sclerosis? Curr Treat Options Neurol 20 9-96

[8] Massey JC(2015)Longitudinal evaluation of visual function in multiple sclerosis Optom Vis Sci 92 976-1319

[9] Sutton IJ(2016)Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica Neuroimage Clin 11 743-193

[10] Ma DDF(2017)Optical coherence tomography: a quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis J Neuroimmunol 304 93-2527